Table 3.

Association of serum IL-16 and risk of PCa among African-Americans.

	Tertile 1				Tertile 2 vs Tertile 1				Tertile 3 vs Tertile 1					Continuous ln(IL-16)
	no. cases/ no. controls	OR	95% CI	p-value	no. cases/ no. controls	OR	95% CI	p-value	no. cases/ no. controls	OR	95% CI	p-value	p (trend)	OR	95% CI	p-value	phet
All PCa	65/97	1.0	reference		44/106	0.56	0.34-0.94	0.03	45/99	0.77	0.45-1.30	0.33	0.27	0.83	0.64-1.09	0.18
Nonaggressive PCa	50/97	1.0	reference		40/106	0.65	0.38-1.13	0.13	33/99	0.73	0.41-1.30	0.28	0.26	0.86	0.64-1.16	0.33
Aggressive PCa	15/97	1.0	reference		3/106	0.18	0.05-0.68	0.01	12/99	0.96	0.39-2.39	0.94	0.78	0.76	0.48-1.19	0.23	0.60
Stage I/II PCa	57/97	1.0	reference		43/106	0.63	0.37-1.07	0.08	39/99	0.76	0.44-1.32	0.34	0.29	0.84	0.63-1.11	0.22
Stage III/IV PCa	8/97	1.0	reference		1/106	0.12	0.01-1.00	0.05	6/99	0.82	0.24-2.77	0.75	0.67	0.80	0.43-1.50	0.49	0.89
Gleason Score ≤ 6	32/97	1.0	reference		30/106	0.74	0.40-1.38	0.34	25/99	0.85	0.44-1.63	0.63	0.63	0.89	0.63-1.26	0.50
Gleason Score ≥ 7	31/97	1.0	reference		13/106	0.38	0.18-0.79	0.01	20/99	0.73	0.36-1.46	0.37	0.27	0.79	0.56-1.12	0.18	0.60

All models adjusted for study center, use of thawed aliquot (yes/no), time from blood draw to diagnosis/selection, age and year at randomization.

Aggressive PCa defined as Gleason Score ≥8 or Stage III/IV disease.

Tertiles with < 5 cases not shown due to unstable estimates.